263 related articles for article (PubMed ID: 23856031)
1. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.
Okamoto K; Kodama K; Takase K; Sugi NH; Yamamoto Y; Iwata M; Tsuruoka A
Cancer Lett; 2013 Oct; 340(1):97-103. PubMed ID: 23856031
[TBL] [Abstract][Full Text] [Related]
2. Novel Human-Derived
Schubert L; Le AT; Estrada-Bernal A; Doak AE; Yoo M; Ferrara SE; Goodspeed A; Kinose F; Rix U; Tan AC; Doebele RC
Mol Pharmacol; 2021 Jun; 99(6):435-447. PubMed ID: 33795352
[TBL] [Abstract][Full Text] [Related]
3. MAN2A1-FER Fusion Gene Is Expressed by Human Liver and Other Tumor Types and Has Oncogenic Activity in Mice.
Chen ZH; Yu YP; Tao J; Liu S; Tseng G; Nalesnik M; Hamilton R; Bhargava R; Nelson JB; Pennathur A; Monga SP; Luketich JD; Michalopoulos GK; Luo JH
Gastroenterology; 2017 Oct; 153(4):1120-1132.e15. PubMed ID: 28245430
[TBL] [Abstract][Full Text] [Related]
4. Antitumor Activity of RXDX-105 in Multiple Cancer Types with
Li GG; Somwar R; Joseph J; Smith RS; Hayashi T; Martin L; Franovic A; Schairer A; Martin E; Riely GJ; Harris J; Yan S; Wei G; Oliver JW; Patel R; Multani P; Ladanyi M; Drilon A
Clin Cancer Res; 2017 Jun; 23(12):2981-2990. PubMed ID: 28011461
[No Abstract] [Full Text] [Related]
5. Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway.
Lin C; Wang S; Xie W; Zheng R; Gan Y; Chang J
Oncotarget; 2016 Sep; 7(37):59236-59244. PubMed ID: 27494860
[TBL] [Abstract][Full Text] [Related]
6. Selective RET kinase inhibition for patients with RET-altered cancers.
Subbiah V; Velcheti V; Tuch BB; Ebata K; Busaidy NL; Cabanillas ME; Wirth LJ; Stock S; Smith S; Lauriault V; Corsi-Travali S; Henry D; Burkard M; Hamor R; Bouhana K; Winski S; Wallace RD; Hartley D; Rhodes S; Reddy M; Brandhuber BJ; Andrews S; Rothenberg SM; Drilon A
Ann Oncol; 2018 Aug; 29(8):1869-1876. PubMed ID: 29912274
[TBL] [Abstract][Full Text] [Related]
7. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.
Lipson D; Capelletti M; Yelensky R; Otto G; Parker A; Jarosz M; Curran JA; Balasubramanian S; Bloom T; Brennan KW; Donahue A; Downing SR; Frampton GM; Garcia L; Juhn F; Mitchell KC; White E; White J; Zwirko Z; Peretz T; Nechushtan H; Soussan-Gutman L; Kim J; Sasaki H; Kim HR; Park SI; Ercan D; Sheehan CE; Ross JS; Cronin MT; Jänne PA; Stephens PJ
Nat Med; 2012 Feb; 18(3):382-4. PubMed ID: 22327622
[TBL] [Abstract][Full Text] [Related]
8. Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology.
Frett B; Carlomagno F; Moccia ML; Brescia A; Federico G; De Falco V; Admire B; Chen Z; Qi W; Santoro M; Li HY
Angew Chem Int Ed Engl; 2015 Jul; 54(30):8717-21. PubMed ID: 26126987
[TBL] [Abstract][Full Text] [Related]
9. Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.
Plenker D; Riedel M; Brägelmann J; Dammert MA; Chauhan R; Knowles PP; Lorenz C; Keul M; Bührmann M; Pagel O; Tischler V; Scheel AH; Schütte D; Song Y; Stark J; Mrugalla F; Alber Y; Richters A; Engel J; Leenders F; Heuckmann JM; Wolf J; Diebold J; Pall G; Peifer M; Aerts M; Gevaert K; Zahedi RP; Buettner R; Shokat KM; McDonald NQ; Kast SM; Gautschi O; Thomas RK; Sos ML
Sci Transl Med; 2017 Jun; 9(394):. PubMed ID: 28615362
[TBL] [Abstract][Full Text] [Related]
10. The action and resistance mechanisms of Lenvatinib in liver cancer.
Buttell A; Qiu W
Mol Carcinog; 2023 Dec; 62(12):1918-1934. PubMed ID: 37671815
[TBL] [Abstract][Full Text] [Related]
11. CCDC6-RET fusion protein regulates Ras/MAPK signaling through the fusion- GRB2-SHC1 signal niche.
Qiu T; Kong Y; Wei G; Sun K; Wang R; Wang Y; Chen Y; Wang W; Zhang Y; Jiang C; Yang P; Xie T; Chen X
Proc Natl Acad Sci U S A; 2024 Jun; 121(23):e2322359121. PubMed ID: 38805286
[TBL] [Abstract][Full Text] [Related]
12. The heterogeneous transition state of resistance to RET kinase inhibitors converges on ERK1/2-driven Aurora A/B kinases.
Hu X; Liu X; Khatri U; Wu J
Drug Resist Updat; 2023 May; 68():100958. PubMed ID: 36990046
[TBL] [Abstract][Full Text] [Related]
13. Analyzing Somatic Genome Rearrangements in Human Cancers by Using Whole-Exome Sequencing.
Yang L; Lee MS; Lu H; Oh DY; Kim YJ; Park D; Park G; Ren X; Bristow CA; Haseley PS; Lee S; Pantazi A; Kucherlapati R; Park WY; Scott KL; Choi YL; Park PJ
Am J Hum Genet; 2016 May; 98(5):843-856. PubMed ID: 27153396
[TBL] [Abstract][Full Text] [Related]
14. Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation.
Frett B; Moccia M; Carlomagno F; Santoro M; Li HY
Eur J Med Chem; 2014 Oct; 86():714-23. PubMed ID: 25232968
[TBL] [Abstract][Full Text] [Related]
15. A Caged Ret Kinase Inhibitor and its Effect on Motoneuron Development in Zebrafish Embryos.
Bliman D; Nilsson JR; Kettunen P; Andréasson J; Grøtli M
Sci Rep; 2015 Aug; 5():13109. PubMed ID: 26300345
[TBL] [Abstract][Full Text] [Related]
16. Peritoneal effusion: an uncommon adverse effect of selective RET inhibitors.
Belli C; Curigliano G
Ann Oncol; 2024 May; 35(5):478-480. PubMed ID: 38369014
[No Abstract] [Full Text] [Related]
17. Advances in Targeting RET-Dependent Cancers.
Subbiah V; Cote GJ
Cancer Discov; 2020 Apr; 10(4):498-505. PubMed ID: 32094155
[No Abstract] [Full Text] [Related]
18. Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.
Miyazaki I; Odintsov I; Ishida K; Lui AJW; Kato M; Suzuki T; Zhang T; Wakayama K; Kurth RI; Cheng R; Fujita H; Delasos L; Vojnic M; Khodos I; Yamada Y; Ishizawa K; Mattar MS; Funabashi K; Chang Q; Ohkubo S; Yano W; Terada R; Giuliano C; Lu YC; Bonifacio A; Kunte S; Davare MA; Cheng EH; de Stanchina E; Lovati E; Iwasawa Y; Ladanyi M; Somwar R
Nat Cancer; 2023 Sep; 4(9):1345-1361. PubMed ID: 37743366
[TBL] [Abstract][Full Text] [Related]
19. Loss of CCDC6, the first identified RET partner gene, affects pH2AX S139 levels and accelerates mitotic entry upon DNA damage.
Merolla F; Luise C; Muller MT; Pacelli R; Fusco A; Celetti A
PLoS One; 2012; 7(5):e36177. PubMed ID: 22655027
[TBL] [Abstract][Full Text] [Related]
20. A multidimensional platform of patient-derived tumors identifies drug susceptibilities for clinical lenvatinib resistance.
Sun L; Wan AH; Yan S; Liu R; Li J; Zhou Z; Wu R; Chen D; Bu X; Ou J; Li K; Lu X; Wan G; Ke Z
Acta Pharm Sin B; 2024 Jan; 14(1):223-240. PubMed ID: 38261805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
